FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4248891925> ?p ?o ?g. }

• W4248891925 abstract "Background Epilepsy is defined as the tendency to spontaneous, excessive neuronal discharge manifesting as seizures. It is a common disorder with an incidence of 50 per 100,000 per year and a prevalence of 0.5% to 1% (Hauser 1993) in the developed world. Carbamazepine (CBZ) is a commonly used antiepileptic drug that is associated with a number of troublesome adverse events including dizziness, double vision and unsteadiness. These often occur during peaks in plasma concentration. The occurrence of such adverse events may limit the daily dose that can be tolerated and reduce the chances of seizure control for patients requiring higher doses (Vojvodic 2002). A controlled‐release formulation of carbamazepine delivers the same dose over a longer period of time when compared to a standard formulation, thereby reducing post‐dose peaks and potentially reducing adverse events associated with peak plasma levels. Objectives To determine the efficacy of immediate‐release carbamazepine (IR CBZ) versus controlled‐release carbamazepine (CR CBZ) in patients with newly diagnosed epilepsy. To determine the efficacy of switching to CR CBZ in patients treated with IR CBZ but experiencing unacceptable adverse events. Search methods We searched the Cochrane Epilepsy Group Specialised Register (21 July 2011), Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2011, Issue 3 of 4) and MEDLINE (1948 to July week 2, 2011). Selection criteria Randomised controlled trials comparing IR CBZ to CR CBZ in patients commencing monotherapy and patients presently treated with IR CBZ but experiencing unacceptable adverse events. Primary outcome measures include seizure frequency, incidence of adverse events, proportion with treatment failure and quality of life measures. Data collection and analysis The methodological quality of each study was assessed with respect to study design, type of control, method and concealment of allocation, blinding and completeness of follow up, and the presence of blinding for assessment of non‐fatal outcomes. We did not make use of an overall quality score. Two review authors (GP, MS) independently extracted the data and recorded relevant information on a standardised data extraction form. Results were assessed for inclusion. The heterogeneity of the included trials resulted in only a narrative, descriptive analysis being possible for both categorical and time‐to‐event data. Main results Ten trials fulfilled the criteria for inclusion in this review. One trial included patients with newly diagnosed epilepsy and nine included patients on treatment with IR CBZ. Eight trials reported heterogeneous measures of seizure frequency with conflicting results. A statistically significant difference was observed in only one trial, with patients prescribed CR CBZ experiencing fewer seizures than patients prescribed IR CBZ. Nine trials reported measures of adverse events. There was a trend in favour of CR CBZ with four trials reporting a statistically significant reduction in adverse events compared to IR CBZ. A further two trials reported fewer adverse events with CR CBZ, but the reduction was not statistically significant. One trial found no difference, with a further trial reporting increased adverse events in the CR CBZ group although not statistically significant. Authors' conclusions At present, data from trials do not confirm or refute an advantage for CR CBZ over IR CBZ for seizure frequency or adverse events in patients with newly diagnosed epilepsy. For trials involving epilepsy patients already prescribed IR CBZ, no conclusions can be drawn concerning the superiority of CR CBZ with respect to seizure frequency. There is a trend for CR CBZ to be associated with fewer adverse events when compared to IR CBZ. A change to CR CBZ may therefore be a worthwhile strategy in patients with acceptable seizure control on IR CBZ but experiencing unacceptable adverse events. The included trials were of small size, poor methodological quality and possessed a high risk of bias, limiting the validity of this conclusion. Randomised controlled trials comparing CR CBZ to IR CBZ and using clinically relevant outcomes are required to inform the choice of CBZ preparation for patients with newly diagnosed epilepsy." @default.
• W4248891925 created "2022-05-12" @default.
• W4248891925 creator A5005069325 @default.
• W4248891925 creator A5010749476 @default.
• W4248891925 creator A5070178419 @default.
• W4248891925 date "2010-01-20" @default.
• W4248891925 modified "2023-10-07" @default.
• W4248891925 title "Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy" @default.
• W4248891925 cites W1967986271 @default.
• W4248891925 cites W1971043152 @default.
• W4248891925 cites W1974870612 @default.
• W4248891925 cites W1975940543 @default.
• W4248891925 cites W1978983959 @default.
• W4248891925 cites W2000315951 @default.
• W4248891925 cites W2002184575 @default.
• W4248891925 cites W2005561977 @default.
• W4248891925 cites W2007845781 @default.
• W4248891925 cites W2007847309 @default.
• W4248891925 cites W2046126605 @default.
• W4248891925 cites W2053969120 @default.
• W4248891925 cites W2079012051 @default.
• W4248891925 cites W2119843181 @default.
• W4248891925 cites W2189061081 @default.
• W4248891925 cites W98145672 @default.
• W4248891925 doi "https://doi.org/10.1002/14651858.cd007124.pub2" @default.
• W4248891925 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20091617" @default.
• W4248891925 hasPublicationYear "2010" @default.
• W4248891925 type Work @default.
• W4248891925 citedByCount "5" @default.
• W4248891925 countsByYear W42488919252014 @default.
• W4248891925 countsByYear W42488919252016 @default.
• W4248891925 countsByYear W42488919252020 @default.
• W4248891925 countsByYear W42488919252022 @default.
• W4248891925 crossrefType "reference-entry" @default.
• W4248891925 hasAuthorship W4248891925A5005069325 @default.
• W4248891925 hasAuthorship W4248891925A5010749476 @default.
• W4248891925 hasAuthorship W4248891925A5070178419 @default.
• W4248891925 hasConcept C118552586 @default.
• W4248891925 hasConcept C120665830 @default.
• W4248891925 hasConcept C121332964 @default.
• W4248891925 hasConcept C126322002 @default.
• W4248891925 hasConcept C142724271 @default.
• W4248891925 hasConcept C168563851 @default.
• W4248891925 hasConcept C187212893 @default.
• W4248891925 hasConcept C197934379 @default.
• W4248891925 hasConcept C204787440 @default.
• W4248891925 hasConcept C27081682 @default.
• W4248891925 hasConcept C2776478404 @default.
• W4248891925 hasConcept C2778186239 @default.
• W4248891925 hasConcept C2779253243 @default.
• W4248891925 hasConcept C3019981671 @default.
• W4248891925 hasConcept C42219234 @default.
• W4248891925 hasConcept C61511704 @default.
• W4248891925 hasConcept C71924100 @default.
• W4248891925 hasConcept C98274493 @default.
• W4248891925 hasConceptScore W4248891925C118552586 @default.
• W4248891925 hasConceptScore W4248891925C120665830 @default.
• W4248891925 hasConceptScore W4248891925C121332964 @default.
• W4248891925 hasConceptScore W4248891925C126322002 @default.
• W4248891925 hasConceptScore W4248891925C142724271 @default.
• W4248891925 hasConceptScore W4248891925C168563851 @default.
• W4248891925 hasConceptScore W4248891925C187212893 @default.
• W4248891925 hasConceptScore W4248891925C197934379 @default.
• W4248891925 hasConceptScore W4248891925C204787440 @default.
• W4248891925 hasConceptScore W4248891925C27081682 @default.
• W4248891925 hasConceptScore W4248891925C2776478404 @default.
• W4248891925 hasConceptScore W4248891925C2778186239 @default.
• W4248891925 hasConceptScore W4248891925C2779253243 @default.
• W4248891925 hasConceptScore W4248891925C3019981671 @default.
• W4248891925 hasConceptScore W4248891925C42219234 @default.
• W4248891925 hasConceptScore W4248891925C61511704 @default.
• W4248891925 hasConceptScore W4248891925C71924100 @default.
• W4248891925 hasConceptScore W4248891925C98274493 @default.
• W4248891925 hasLocation W42488919251 @default.
• W4248891925 hasLocation W42488919252 @default.
• W4248891925 hasOpenAccess W4248891925 @default.
• W4248891925 hasPrimaryLocation W42488919251 @default.
• W4248891925 hasRelatedWork W1965295928 @default.
• W4248891925 hasRelatedWork W1967986271 @default.
• W4248891925 hasRelatedWork W1996263415 @default.
• W4248891925 hasRelatedWork W2036500962 @default.
• W4248891925 hasRelatedWork W2039381148 @default.
• W4248891925 hasRelatedWork W2110954332 @default.
• W4248891925 hasRelatedWork W2132282183 @default.
• W4248891925 hasRelatedWork W2409957712 @default.
• W4248891925 hasRelatedWork W2565914894 @default.
• W4248891925 hasRelatedWork W2910696677 @default.
• W4248891925 isParatext "false" @default.
• W4248891925 isRetracted "false" @default.
• W4248891925 workType "reference-entry" @default.